Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea.
Eui-Soon KimSun-Kyeong ParkDaniel Sung-Ho ChoJong-Chan YounHye Sun LeeHae-Young LeeHyun-Jai ChoJin Oh ChoiEun Seok JeonSang-Eun LeeMin-Seok KimJae-Joong KimKyung Kuk HwangMyeong-Chan ChoShung Chull ChaeSeok-Min KangJin Joo ParkYoungkeun AhnByung-Su YooJae Yeong ChoKye Hun KimByung-Hee OhBarry D GreenbergSang-Hong BaekPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2024)
Discrepancies in dapagliflozin eligibility were observed between real-world data and clinical trial results. The addition of dapagliflozin to HF therapy proved to be highly cost-effective across the entire EF spectrum.